EP4072588A4 - NOVEL INTERLEUKIN 15 (IL-15) FUSION PROTEINS AND USES THEREOF - Google Patents

NOVEL INTERLEUKIN 15 (IL-15) FUSION PROTEINS AND USES THEREOF Download PDF

Info

Publication number
EP4072588A4
EP4072588A4 EP20899197.6A EP20899197A EP4072588A4 EP 4072588 A4 EP4072588 A4 EP 4072588A4 EP 20899197 A EP20899197 A EP 20899197A EP 4072588 A4 EP4072588 A4 EP 4072588A4
Authority
EP
European Patent Office
Prior art keywords
fusion proteins
novel interleukin
interleukin
novel
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20899197.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4072588A1 (en
Inventor
Yue-Sheng Li
Lingyun Rui
Jing Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cugene Inc
Original Assignee
Cugene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cugene Inc filed Critical Cugene Inc
Priority to EP24191000.9A priority Critical patent/EP4461750A3/en
Publication of EP4072588A1 publication Critical patent/EP4072588A1/en
Publication of EP4072588A4 publication Critical patent/EP4072588A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP20899197.6A 2019-12-13 2020-12-11 NOVEL INTERLEUKIN 15 (IL-15) FUSION PROTEINS AND USES THEREOF Withdrawn EP4072588A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24191000.9A EP4461750A3 (en) 2019-12-13 2020-12-11 Novel interleukin-15 (il-15) fusion proteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947686P 2019-12-13 2019-12-13
PCT/US2020/064515 WO2021119429A1 (en) 2019-12-13 2020-12-11 Novel interleukin-15 (il-15) fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24191000.9A Division EP4461750A3 (en) 2019-12-13 2020-12-11 Novel interleukin-15 (il-15) fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
EP4072588A1 EP4072588A1 (en) 2022-10-19
EP4072588A4 true EP4072588A4 (en) 2024-02-14

Family

ID=76330576

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20899197.6A Withdrawn EP4072588A4 (en) 2019-12-13 2020-12-11 NOVEL INTERLEUKIN 15 (IL-15) FUSION PROTEINS AND USES THEREOF
EP24191000.9A Pending EP4461750A3 (en) 2019-12-13 2020-12-11 Novel interleukin-15 (il-15) fusion proteins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP24191000.9A Pending EP4461750A3 (en) 2019-12-13 2020-12-11 Novel interleukin-15 (il-15) fusion proteins and uses thereof

Country Status (8)

Country Link
US (1) US20230048046A1 (https=)
EP (2) EP4072588A4 (https=)
JP (1) JP7807076B2 (https=)
KR (1) KR20220114063A (https=)
CN (1) CN115087464B (https=)
AU (1) AU2020402097A1 (https=)
CA (1) CA3164337A1 (https=)
WO (1) WO2021119429A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
CN111423510B (zh) * 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
JP2024527593A (ja) * 2021-07-09 2024-07-25 レジェンド バイオテック アイルランド リミテッド 変異型ｉｌ－１５組成物及びその方法
WO2023048518A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도
WO2023133424A2 (en) * 2022-01-05 2023-07-13 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
JP2025507733A (ja) * 2022-02-28 2025-03-21 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用
WO2023196905A1 (en) * 2022-04-07 2023-10-12 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
CN116063512B (zh) * 2022-10-13 2025-11-07 深圳市百士通科技开发有限公司 多功能重组抗体及其制备方法和应用
KR20250135294A (ko) * 2023-02-21 2025-09-12 레메젠 코, 리미티드 암을 위한 il-15 작용제
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025252855A1 (en) * 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
CN118995825B (zh) * 2024-10-24 2025-02-07 星奕昂(上海)生物科技有限公司 一种特异性定量标定白细胞介素15活性的细胞系及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060236411A1 (en) * 2002-10-14 2006-10-19 Ingeborg Dreher Antagonists il-15
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
WO2017046200A1 (en) * 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
US20180118805A1 (en) * 2016-10-14 2018-05-03 Xencor, Inc. IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019204592A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019246379A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Novel interleukin-15 (1l-15) fusion proteins and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CL2008003526A1 (es) 2007-11-30 2010-01-11 Medarex Inc Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
NO2344540T3 (https=) * 2008-10-02 2018-04-28
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
RU2689717C2 (ru) * 2014-01-08 2019-05-28 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Гетеродимерный белок il-15 и его применения
TW201741337A (zh) * 2016-05-13 2017-12-01 麥迪紐有限責任公司 ＣＤ４０Ｌ-Ｆｃ融合多肽及其使用方法
CA3086040A1 (en) * 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
CN112004547A (zh) * 2018-02-26 2020-11-27 新索思股份有限公司 Il-15缀合物及其用途
CA3090407A1 (en) 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
AU2019359475A1 (en) * 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060236411A1 (en) * 2002-10-14 2006-10-19 Ingeborg Dreher Antagonists il-15
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
WO2017046200A1 (en) * 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
US20180118805A1 (en) * 2016-10-14 2018-05-03 Xencor, Inc. IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019204592A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019246379A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Novel interleukin-15 (1l-15) fusion proteins and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUO YIN ET AL: "Immunobiology of the IL-15/IL-15R[alpha] complex as an antitumor and antiviral agent", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 38, 1 September 2017 (2017-09-01), pages 10 - 21, XP085253997, ISSN: 1359-6101, DOI: 10.1016/J.CYTOGFR.2017.08.002 *
See also references of WO2021119429A1 *

Also Published As

Publication number Publication date
CN115087464A (zh) 2022-09-20
US20230048046A1 (en) 2023-02-16
JP2023506452A (ja) 2023-02-16
CN115087464B (zh) 2025-02-25
KR20220114063A (ko) 2022-08-17
WO2021119429A1 (en) 2021-06-17
EP4461750A2 (en) 2024-11-13
AU2020402097A1 (en) 2022-07-07
JP7807076B2 (ja) 2026-01-27
EP4072588A1 (en) 2022-10-19
EP4461750A3 (en) 2025-03-26
CA3164337A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
EP4072588A4 (en) NOVEL INTERLEUKIN 15 (IL-15) FUSION PROTEINS AND USES THEREOF
IL278090A (en) IL-15/IL-15Rα heterodimeric Fc-Fc proteins and their uses
EP3758729B8 (en) Il-15 conjugates and uses thereof
IL290118A (en) Variants of interleukin-2, fusion proteins containing them, preparations containing them and their uses
EP3743438A4 (en) CYTOKI FUSION PROTEINS
EP3908664A4 (en) MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES
EP3997127A4 (en) ANTIBODIES TARGETING DLL3 AND THEIR USES
EP3768728A4 (en) FUSION PROTEINS WITH CD47 ANTIBODIES AND CYTOKINES
EP4067378A4 (en) ANTIBODY DIRECTED AGAINST C-KIT AND CORRESPONDING USE
EP3863657A4 (en) BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF
EP3998282A4 (en) NEW FUSION PROTEIN AND ITS USE
EP3976104A4 (en) ANTI-CSF1R ANTIBODIES, IL10 FUSION PROTEINS AND THEIR USES
EP4041403A4 (en) ANTI-KIR3DL3 ANTIBODIES AND USES THEREOF
EP3959225A4 (en) CD80 VARIANT PROTEINS AND THEIR USES
EP4034570A4 (en) HETERODIMERIC PROTEINS
EP3994180A4 (en) ANTIBODY-HER2-SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
EP4107190A4 (en) FUSION PROTEINS AND USES THEREOF
EP4025611A4 (en) ANTI-CXCR2 ANTIBODIES AND THEIR USES
EP3983435A4 (en) ANTI-TALEN ANTIBODIES AND THEIR USES
CA3281927A1 (en) Il-15 fusion proteins with improved properties
HK40068380A (en) Nkg2d fusion proteins and uses thereof
HK40050134A (en) Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
HK40076286A (en) Il-15 conjugates and uses thereof
HK40015256A (en) Fusion proteins containing cd47 antibodies and cytokines
HK40115049A (en) Novel proteins

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/40 20060101ALI20231006BHEP

Ipc: C07K 16/32 20060101ALI20231006BHEP

Ipc: C07K 14/54 20060101ALI20231006BHEP

Ipc: C07K 16/28 20060101ALI20231006BHEP

Ipc: C07K 16/18 20060101ALI20231006BHEP

Ipc: C07K 14/715 20060101ALI20231006BHEP

Ipc: C07K 19/00 20060101ALI20231006BHEP

Ipc: A61P 31/12 20060101ALI20231006BHEP

Ipc: A61K 45/06 20060101AFI20231006BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20240112

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/40 20060101ALI20240108BHEP

Ipc: C07K 16/32 20060101ALI20240108BHEP

Ipc: C07K 14/54 20060101ALI20240108BHEP

Ipc: C07K 16/28 20060101ALI20240108BHEP

Ipc: C07K 16/18 20060101ALI20240108BHEP

Ipc: C07K 14/715 20060101ALI20240108BHEP

Ipc: C07K 19/00 20060101ALI20240108BHEP

Ipc: A61P 31/12 20060101ALI20240108BHEP

Ipc: A61K 45/06 20060101AFI20240108BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20240729